AI drug discovery screening for COVID-19 reveals zafirlukast as a repurposing candidate.

Med Drug Discov · 2021 · PMC7836294 · PMID 33521623

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

may be significantno p-value reported

Moreover, according to the study of Almerie and Kerrigan [ 24 ], montelukast by acting through the antiviral effect, or by suppression of augmented cytokine release may reduce the severity of immune-mediated multiorgan damage, what may be significant especially in COVID-19 patients with central obesity and metabolic syndrome.

also in 13,097 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.